mesoblast


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

mes·o·blast

 (mĕz′ə-blăst′, mĕs′-)
n.
The middle germinal layer of an early embryo, consisting of undifferentiated cells destined to become the mesoderm.

mes′o·blas′tic adj.

mesoblast

(ˈmɛsəʊˌblæst)
n
(Zoology) another name for mesoderm
ˌmesoˈblastic adj
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.mesoblast - the middle germ layer that develops into muscle and bone and cartilage and blood and connective tissuemesoblast - the middle germ layer that develops into muscle and bone and cartilage and blood and connective tissue
germ layer - (embryology) any of the 3 layers of cells differentiated in embryos following gastrulation
chordamesoderm, chordomesoderm - the area of mesoderm that forms the notochord
mesenchyme - mesodermal tissue that forms connective tissue and blood and smooth muscles
Translations
References in periodicals archive ?
Release date- 27082019 - Melbourne - Mesoblast Limited (ASX: MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced today positive outcomes from its recent meeting with the United States Food and Drug Administration (FDA) on the pathway for marketing authorization of its allogeneic cell therapy product candidate Revascor in end-stage heart failure patients implanted with a left ventricular assist device (LVAD).
NEW YORK, USA; and MELBOURNE, Australia, July 25, 2019 -- Cardiovascular journal Circulation Research has published a special article highlighting the potential clinical benefits of an allogeneic mesenchymal precursor cell (MPC) technology as immunotherapy in patients with advanced chronic heart failure, Mesoblast Limited (NASDAQ: MESO) announced.
Mesoblast announced it has expanded its partnership with JCR Pharmaceuticals in Japan to the use of mesenchymal stem cells, or MSCs, for the treatment of newborns who lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic ischemic encephalopathy, or HIE.
NEW YORK, N.Y., April 16, 2019 -- Mesoblast Limited (NASDAQ:MESO) announced that the FDA has agreed that Australian stem cell company Mesoblast can submit on a rolling basis a Biologies License Application (BLA) for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft versus Host Disease (SR-aGVHD).
NEW YORK, N.Y., April 16, 2019 -- Mesoblast Limited (NASDAQ:MESO) announced that the FDA has agreed that Australian stem cell company Mesoblast can submit on a rolling basis a Biologics License Application (BLA) for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft versus Host Disease (SR-aGVHD).
Mesoblast Ltd (ASX: MSB) has appointed Josh Muntner as its new chief financial officer, the Australian-based regenerative medicine company announced on Thursday.
Australia-based regenerative medicine company Mesoblast Ltd.
[USPRwire, Wed Dec 30 2015] Global Markets Direct's, 'Mesoblast Limited - Product Pipeline Review - 2015', provides an overview of the Mesoblast Limited's pharmaceutical research and development focus.
Mesoblast Limited, Melbourne, Australia, a regenerative medicine company, announced it has acquired the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics, Columbia, MD, by the Mesoblast Group.
Regenerative medicine company Mesoblast Limited has been granted a key patent by the Japanese Patent Office.
Medidata Solutions continues to lead the market with its cloud-based clinical development platform through a new customer commitment from Mesoblast Limited, a world leader in developing biologic products for the broad field of regenerative medicine.
Melbourne, Australia, Jan 31, 2012 - (ABN Newswire) - Mesoblast Limited (ASX:MSB) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its proprietary adult stem cells for the treatment of Type 2 diabetes.